

Available online at [www.sciencerepository.org](http://www.sciencerepository.org)

Science Repository



## Case Report

# Small Degenerated Surgical Bioprosthetic Valve should be Treated with Supra-Annular Valve-in-Valve Transcatheter Aortic Valve Replacement

Frane Runjić<sup>1#</sup>, Andrija Matetić<sup>1</sup>, Matjaž Bunc<sup>2</sup>, Nikola Crnčević<sup>1</sup> and Ivica Kristić<sup>1\*#</sup>

<sup>1</sup>Department of Cardiology, University Hospital of Split, Split, Croatia

<sup>2</sup>Department of Cardiology, Ljubljana University Medical Centre, Ljubljana, Slovenia

<sup>#</sup>Contributed equally

### ARTICLE INFO

#### Article history:

Received: 24 September, 2021

Accepted: 9 October, 2021

Published: 9 December, 2021

#### Keywords:

Valve-in-valve

aortic stenosis

patient-prosthesis mismatch

### ABSTRACT

**Background:** Patient-prosthesis mismatch (PPM) is a serious potential complication following surgical aortic valve replacement (SAVR). If it develops, valve-in-valve transcatheter aortic valve replacement (TAVR) is a reasonable therapeutic option. However, there is low evidence on the management of small degenerated surgical bioprosthetic valves, not prone to balloon-valve fracture (BVF).

**Case Presentation:** This case report presents a successful valve-in-valve TAVR in acute heart failure due to degenerative surgical bioprosthetic valve Trifecta (21 mm) that is not susceptible to BVF. Standard preparation for transfemoral TAVR with a self-expandable valve was conducted, including the over-the-wire pacing. Thereafter, a successful valve-in-valve primary implantation of the self-expanding, supra-annular valve Evolut R 26 (Medtronic™) has been achieved. Follow-up at 3 months showed mild paravalvular leak in the region with clinical and heart function improvements of the patient. Follow-up echocardiographic parameters showed the reduction of anterograde flow impairment and improved effective orifice area ( $\sim 0.85 \text{ cm}^2/\text{m}^2$ ).

**Conclusion:** In conclusion, supra-annular valve-in-valve TAVR is a potential therapeutic option for PPM of small degenerated surgical bioprosthetic valves which are not prone to BVF.

© 2021 Ivica Kristić. Hosting by Science Repository.

Get access to the full version of this article: <http://dx.doi.org/10.31487/j.JICOA.2021.04.02>

\*Correspondence to: Ivica Kristić, M.D., Department of Cardiology, University Hospital of Split, Spinčićeva 1, 21000, Split, Croatia; E-mail: [kristicivica@gmail.com](mailto:kristicivica@gmail.com)